Ana Santos Rutschman

Jun 27, 2024 | inquirer.com | Ana Santos Rutschman

The manufacturers of the most popular weight loss drugs are being challenged in court. A federal court in Philadelphia will soon evaluate claims against the makers of Ozempic, Wegovy, and similar products. Dozens of patients who suffered gastrointestinal problems after taking these drugs brought lawsuits alleging that these companies failed to properly warn patients about the risks.

Jun 25, 2024 | omahadailyrecord.com | Ana Santos Rutschman

The manufacturers of the most popular weight loss drugs are being challenged in court. A federal court in Philadelphia will soon evaluate claims against the makers of Ozempic, Wegovy and similar products. Dozens of patients who suffered gastrointestinal problems after taking these drugs brought lawsuits alleging that these companies failed to properly warn patients about the risks.

Jun 24, 2024 | studyfinds.org | Ana Santos Rutschman

(Photo by myskin on Shutterstock)The manufacturers of the most popular weight loss drugs are being challenged in court. A federal court in Philadelphia will soon evaluate claims against the makers of Ozempic, Wegovy, and similar products. Dozens of patients who suffered gastrointestinal problems after taking these drugs brought lawsuits alleging that these companies failed to properly warn patients about the risks.

Jun 22, 2024 | medicalxpress.com | Ana Santos Rutschman

The manufacturers of the most popular weight loss drugs are being challenged in court. A federal court in Philadelphia will soon evaluate claims against the makers of Ozempic, Wegovy and similar products. Dozens of patients who suffered gastrointestinal problems after taking these drugs brought lawsuits alleging that these companies failed to properly warn patients about the risks.

Jun 20, 2024 | usnews.com | Ana Santos Rutschman |Jennifer Mieres |David Battinelli

A federal court in Philadelphia is gearing up to evaluate a challenge to the makers of Ozempic, Wegovy and similar weight-loss drugs in a case that has huge implications for public trust in medicine and government regulations. It will also likely affect a multibillion dollar market for weight-loss drugs that more than 15 million Americans reported using last month.